Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5191_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
68 Мб
Скачать
216
M. Negulescu
arms, and penis, which are less considered asso­ciated with diabetes mellitus [1, 5].
The progression is slow, and sometimes regression of lesions may happen in 20% of cases [1]. The main complication is ulceration [1, 4] with secondary infection [6]. Some excep­tional cases of squamous cell carcinoma have been reported in long-standing NL [1, 4]. The origin of malignant transformation is even unclear [4].

30.5 Treatment

Fig. 30.1 Two lesions. The rst one in the left side on the
picture is atrophic, white center surrounded by brown bor­ders. The second one showed ulcerative center containing brin, surrounded by erythematous, active borders
Fig. 30.2 Waxy, smooth, white plaque surrounded by erythematous borders
rst appearing red-brown and becoming yellow­orange and smooth. Sometimes, telangiectasia may occur [1, 4, 5].
As mentioned, the lesions are mostly painless due to nerve damage, but ulcerated lesions may cause pain. These ones may occur following minor trauma in up to 35% of cases [4].
In 90% of patients, NL arises on legs, bilater­ally and symmetrically [1]. Less frequently, lesions may appear on the scalp, face, trunk, fore-
The rst step is to prevent lesions by avoidance of trauma [2]. Indeed, NL may also occur by Koebner effect, in addition to ulceration risk [2,
4]. Control of diabetes seems to be without any
improvement [1, 4, 5].
Several treatments have been tested with ran­dom results. Most of them are based on case reports.
Treatment by topical corticosteroids is effec­tive to prevent progression and reduce inamma­tory process, especially on the active borders [1,
2, 4, 5].
Wound care is highly important in NL.Infected wounds must be treated by antiseptics and adapted dressings [2]. Sometimes, systemic anti­biotics are helpful [4].
Ulcerated NLs are improved by granulocyte­macrophage colony-stimulating factor [4].
An association of aspirin and dipyridamole was suggested as NL treatment, but no trial has showed any improvement [2, 4]. The use of low­dose aspirin did not suggest any benet in another trial [4].
The use of stanozolol, ticlopidine, inositol nicotinate, pentoxifylline, and prostaglandin E1 seemed to have benecial effects [2, 4].
Psoralen plus ultraviolet A (PUVA) therapy also seems to be successful. One study of ten patients with NL showed 100% healing rate after 47 sessions [4].
30 Necrobiosis Lipoidica
217
Tests with methyl aminolevulinate photody-
namic therapy have been unsuccessful [4].
Some immunomodulatory drugs like oral cyclosporine and mycophenolate mofetil have been tested on ulcerating NL and showed improvement of lesions. In both cases, recurrence occurred after cessation of treatment [2, 4]. Iniximab, thalidomide, and etanercept also have been tested, with benecial results [2, 4].
Surgery is not recommended in the NL treat­ment because of Koebnerized lesions on surgical scars [2, 4]. Usually, lesions are excised down to deep fascia or periosteum to prevent recurrences [2, 4]. The defect is lled by skin graft. Cosmetic results after removal of lesions in these areas are substantial [2].
Occasionally, pulse dye lasers have been tested to treat telangiectasia, with mixed results [4].

References

1. Bessis D, et al. Manifestations dermatologiques des maladies d’organes, vol. 4. France: Springer-Verlag, Paris. Chap. 76-4-5
2. Kota SK, etal. Necrobiosis lipoidica diabeticorum: a case-based review of literature. Indian J Endocrinol Metab. 2012;16(4):614–20.
3. Sehgal VN, Bhattacharya SN, Verma P. Juvenile, insulin- dependent diabetes mellitus, type 1-related dermatoses. J Eur Acad Dermatol. 2011;25:625–36.
4. Reid SD, et al. Update on necrobiosis lipoidica: a review of etiology, diagnosis, and treatment options. J Am Acad Dermatol. 2013;63:783–91.
5. Callen JP, Jorizzo JL.Dermatological signs of internal disease. 4th ed. Philadelphia: W.B.Saunders.
6. Behm B, Schreml S, Landthaler M, Babilas P. Skin signs in diabetes mellitus. J Eur Acad Dermatol. 2012;26:1203–11.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial­NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by- nc- nd/4.0/), which permits any non­commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if you modied the licensed material. You do not have permission under this license to share adapted material derived from this chapter or parts of it.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Purpura Fulminans

NancyHajjar andVéroniqueDel Marmol
31

31.1 Introduction

Purpura fulminans is a rare life-threatening con­dition often associated with disseminated intra­vascular coagulation leading to vast skin necrosis and tissue thrombosis [13].
It is generally seen in neonates with homozy­gous protein C or S deciency. An acquired form of protein C deciency in the context of infection and septicemia can also trigger this condition [13].

31.2 Epidemiology

There are three main subtypes of purpura fulminans:
1. The neonatal form with a prevalence of
1:1,000,000 births [3].
2. The infectious form with variable prevalence
and a predilection to some bacteria. It mainly occurs in meningococcal infections where PF complicates in 10–20% of cases, followed by streptococcal pneumonia. Varicella is the most common viral infection causing PF, but
cases remain very rare. Fewer publications report relatively less virulent germs.
COVID-19 infection was also reported as a triggering infectious agent of PF [35]. In addition, one case of purpura fulminans asso­ciated with COVID-19 vaccination was described, manifesting 6 weeks after the vac­cine [6].
3. The idiopathic form is very exceptional with only a few cases reported [3, 7].
31.3 When toSuspect Purpura
Fulminans
• Neonates who develop extensive ecchymoses
especially in the rst days of life followed by diffuse arterial and venous thrombosis. Later presentation in infancy is also reported.
• Retiform purpuric skin lesions in the context
of sepsis (mainly severe meningococcal infec­tion) associated with severe cutaneous pain out of proportion with the physical exam.

31.4 Pathogenesis

N. Hajjar (*) Department of Dermatology, CHU Henri Mondor, Créteil, France
V. Del Marmol Department of Dermatology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), CUB Hôpital Erasme, Brussels, Belgium
© The Author(s) 2024 L. Téot et al. (eds.), Skin Necrosis, https://doi.org/10.1007/978-3-031-60954-1_31
In the three forms of purpura fulminans, the coagulation balance is disrupted in favor of pro­coagulant factors [13].
1. Neonatal: Inherited deciency of protein C/S or antithrombin III, which are anticoagulant
219
220
N. Hajjar and V. Del Marmol
factors, will lead to microvascular thrombosis and hemorrhagic necrosis [3, 8].
2. Infectious: In this form, secondary consumption of protein C is the speculated process [3, 9].
3. Idiopathic: A postinfectious autoimmune mechanism is suspected in this entity during which mainly a relative insufciency of pro­tein S is observed due to anti-protein S anti­body formation [3, 7].

31.5 Clinical Presentation

PF usually starts with ill-dened painful ery­thema centered by bluish necrosis. Sometimes, bullous lesions can be seen. In advanced stages, sensitivity is lost, and necrosis becomes very extensive [13].
The patient is often septic with signs of shock (hypotension, tachycardia, altered mental status, weak peripheral pulses) and/or signs of end­organ damage.
Since DIC often complicates PF, bleeding from intravenous lines and mucous membranes can be seen [13].
31.5.2 Management
Hydration and supportive care are very important in all the forms of PF to avoid end-organ damage. In addition, frequent assessment of necrosis sta­tus for early surgical debridement is necessary.
1. In the neonatal form: The mainstream of treat­ment consists of protein C/S supplementation in addition to fresh frozen plasma (FFP) [3,
10, 11].
2. In the infectious form: Broad-spectrum anti­biotics are used (generally carbapenem or vancomycin + beta-lactam-beta-lactamase inhibitor +/ clindamycin).
Intravenous immunoglobulin therapy and activated protein C supplementation can be benecial.
Anticoagulation is discussed in every case based on the occurrence of DIC [13].
3. In the idiopathic form: In addition to the pre­viously mentioned strategies, systemic corti­costeroids can be discussed [3, 7].
31.5.3 Dierential Diagnosis
31.5.1 Workup
In the neonatal form: The dosage of protein C and protein S activity is the recommended diagnostic tool. If feasible, genetic testing allows the conr­mation of this entity [8, 10].
In the infectious form: Complete sepsis workup is important to treat the causative agent, with sometimes the need for extensive laboratory exams, imaging, and repeated cultures.
This conventional workup is not satisfactory in all cases. Bacterial polymerase chain reaction (PCR) on skin biopsy is now practicable and allows etiological diagnosis rapidly. Thus, biopsy of a purpura lesion with direct examination, cul­ture, and PCR is now recommended [2].
A DIC workup is mandatory including platelet count, PT, PTT, -dimer, brinogen, and blood smear [3].
In front of a necrotic skin process and an ill patient, one should consider the following main differential diagnoses: [3]
• Vasculitis
• Coumadin-induced skin necrosis
• Meningococcemia
• Calciphylaxis
• Necrotizing fasciitis
31.6 Long-Term Sequelae ofPurpura Fulminans
Many patients with purpura fulminans require extensive debridement, fasciotomy, or even amputation. Thus, qualitative rehabilitation is very important to decrease neurological and psy­chological long-term outcomes.
31 Purpura Fulminans
221
In neonates, severe protein C deciency is asso­ciated with neurological and ophthalmological complications, mainly epilepsy, cerebral palsy, delayed psychomotor development, and blindness. It also requires long-term protein C supplementa­tion and/or anticoagulation. Liver transplantation can be a curative option in some cases [1].
Take Home Messages
• PF is a life-threatening condition with high
morbidity and mortality.
• PF can begin very subtly: bruising in neonates
and petechial rash in an infectious context
should lead to PF consideration.
• Early diagnosis is crucial to avoid end-organ
damage.
• A multidisciplinary approach is necessary
with adequate supportive care, etiological
treatment, as well as surgical consultation
early in the necrotic process.

References

1. Chalmers E, Cooper P, Forman K, Grimley C, Khair K, Minford A, Morgan M, Mumford AD. Purpura fulminans: recognition, diagnosis and management. Arch Dis Child. 2011;96(11):1066–71. https://doi.
org/10.1136/adc.2010.199919. Epub 2011 Jan 12.
2. Contou D, de Prost N.Purpura fulminans de l’adulte [Purpura fulminans in adult patients]. Rev Prat. 2023;73(1):71–8.
3. Perera TB, Murphy-Lavoie HM. Purpura fulmi­nans. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
4. Watanabe Y, Abe T.Purpura fulminans due to pneumo­coccal infection. J Gen Fam Med. 2017;18(6):458–9.
https://doi.org/10.1002/jgf2.105.
5. Khan IA, Karmakar S, Chakraborty U, Sil A, Chandra A.Purpura fulminans as the presenting manifestation of COVID-19. Postgrad Med J. 2021;97(1149):473.
https://doi.org/10.1136/postgradmedj- 2020- 139202.
Epub 2021 Feb 9. PMID: 33563711; PMCID: PMC7878050.
6. Griss J, Eichinger S, Winkler S, Weninger W, Petzelbauer P. A case of COVID-19 vaccination­associated forme fruste purpura fulminans. Br J Dermatol. 2022;186(1):e1. https://doi.org/10.1111/
bjd.20744. Epub 2021 Sep 28. PMID: 34585371;
PMCID: PMC8652590.
7. Bektas F, Soyuncu S.Idiopathic purpura fulminans. Am J Emerg Med. 2011;29(4):475.e5–6.
8. Irfan Kazi SG, Siddiqui E, Habib I, Tabassum S, Afzal B, Khan IQ.Neonatal purpura fulminans, a rare genetic disorder due to protein C deciency: a case report. J Pak Med Assoc. 2018;68(3):463–5.
9. Colling ME, Bendapudi PK. Purpura fulminans: mechanism and management of dysregulated hemo­stasis. Transfus Med Rev. 2018;32(2):69–76.
10. Price VE, Ledingham DL, Krümpel A, Chan AK. Diagnosis and management of neonatal pur­pura fulminans. Semin Fetal Neonatal Med. 2011;16(6):318–22. https://doi.org/10.1016/j.
siny.2011.07.009. Epub 2011 Aug 11.
11. Kizilocak H, Ozdemir N, Dikme G, Koc B, Celkan T. Homozygous protein C deciency presenting as neonatal purpura fulminans: management with fresh frozen plasma, low molecular weight heparin and protein C concentrate. J Thromb Thrombolysis. 2018;45(2):315–8.
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial­NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by- nc- nd/4.0/), which permits any non­commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if you modied the licensed material. You do not have permission under this license to share adapted material derived from this chapter or parts of it.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Protein C andProtein S Deciencies
SébastienHumbert andPhilippeHumbert
32

32.1 Physiopathology

Protein C and protein S are vitamin K-dependent proteins with natural anticoagulant properties that play a major role in the coagulation pathway. Protein C is activated by the thrombin/thrombo­modulin complex. Activated protein C cleaves membrane-bound active factors V and VIII and inactivates them. Protein C inhibitor and α-1 anti­trypsin are the main inhibitors of protein C.Protein S is a cofactor of activated protein C and can also directly bond to activated factors V and X.
Protein C and protein S deciencies manifest usually as recurrent venous thromboembolism with an annual incidence of recurrent venous thromboembolism of 6.0% and 8.4%, respec­tively. A severe deciency can cause skin necro­sis, especially in newborns as a purpura fulminans. The cause of protein C and protein S can be genetically determined or acquired (Table32.1).
Table 32.1 Causes of protein C and protein S acquired deciency
Acquired protein C deciency
Vitamin K antagonist, vitamin K deciency Hepatic insufciency Hepatic insufciency Disseminated intravascular coagulation Autoimmune syndrome Pregnancy -Asparaginase therapy Autoimmune syndrome
Acquired protein S deciency
Vitamin K antagonist, vitamin K deciency
Disseminated intravascular coagulation
AIDS, varicella zoster virus Nephrotic syndrome

32.2 Diagnosis

Medical context:
– In newborns, homozygote protein C or protein
S deciency manifests in fatal purpura fulminans.
– In adults with heterozygous protein C or pro-
tein S deciency, introduction of vitamin K antagonist can induce skin necrosis within 3–5days.
S. Humbert Department of Internal Medicine, University Hospital, Besancon, France e-mail: shumbert@chu-besancon.fr
P. Humbert (*) Department of Dermatology, University Hospital, Besancon, France
© The Author(s) 2024 L. Téot et al. (eds.), Skin Necrosis, https://doi.org/10.1007/978-3-031-60954-1_32
Semiology – A massive thrombosis of the dermic vascu-
lar network can lead to large ecchymotic
223
224
Picture 32.1 Skin necrosis of the breast after introduc­tion of VKA
patches that can evolve to hemorrhagic bul­lae and then irreversible necrosis.
– When vitamin K antagonists are involved,
lesions are located in areas where the fat layer is the thickest: breast, thighs, abdo­men, and buttocks. Genital involvement is also possible in men (Picture 32.1).
S. Humbert and P. Humbert
Biology: Increase in INR (international nor-
malized ratio) and prothrombin time (if vita­min K antagonist), decrease or even collapse in protein C or protein S.
Histology: We can observe obstructive throm-
bosis of capillaries and venules, vascular brin deposition, and dermal and fat tissue diffuse necrosis.

32.3 Treatment

• Prevent pain (morphines)
• Prevent infection
• Stop vitamin K antagonist and vitamin K
administration
• Heparin therapy
• Protein C concentrate
• Adapted local treatment: surgical excision of
necrotic tissue and transplant
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial­NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by- nc- nd/4.0/), which permits any non­commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if you modied the licensed material. You do not have permission under this license to share adapted material derived from this chapter or parts of it.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Renal Insuciency andNecrosis
EliaRicci
33
Renal insufciency in itself is found to be corre­lated indirectly to cutaneous necroses. In fact, renal insufciency may cause complications, which in turn lead to the formation of gangrenous cutaneous pathologies.
Renal insufciency is classied into ve progres­sive stages based on the values of glomerular ltra­tion. Table33.1 shows the KDOQI classication [1]. Alterations at the cutaneous level begin from stage III onward and become progressively more severe until they become evident in the so-called nal stage. Renal disease itself leads to cutaneous alterations that may be summarised as follows:
• Xerosis: Beginning with dehydration and red-
dening, prevalently in the areas of the extensor
muscles of the limbs, progressively evolving
into oedema and ssures. In the most advanced
stages, there may be areas of lichenication
and/or contact erythema. The ssured areas
may allow bacteria to enter with consequent
cutaneous infections. This form aficts from
50 to 70% of patients in dialysis.
• Pigmentary disorders: These are directly corre-
lated to the duration of the renal insufciency.
They range from hyperpigmentation to a yellow-
ish colouring, prevalently in the areas exposed to
the sun. Pallor is associated with frequent anae-
E. Ricci (*) Difcult Wound Healing Unit, Clinica Eporediese Monza’’s Policlinic Group, Ivrea, Italy e-mail: eliaricci@tin.it
mia in such patients. This form aficts from 20 to 70% of patients in dialytic treatment.
• Itching: Frequent in some patients and may be minimal, but in 8% of cases, it is found to be non-remittent and serious. It leads to a net deterioration in the quality of life.
Another clinical situation of a dermatological
type is nephrogenic dermal brosis (NDF), described in 2000 [2] and currently classied as systemic [3]. It is a pathology that is prevalently cutaneous and characterised by being associated with renal damage. Patients present oedemas and retractions prevalently in the lower limbs; the main symptoms are burning pain and itching. On a cuta­neous level, there is the appearance of papules or plaques that are red or brown in colour and which, on rare occasions, may become ulcerous (Fig.33.1). Around 5% of these forms may exhibit aggressive and sudden worsening with the involvement of muscles, possibly leading to paralysis. As of now, the cause remains poorly dened: possible causes may include the use of gadolinium as a means of contrast [4], erythropoietin, and stages of hyperco­agulability. Under X-ray inspection, diffuse calci­cations are noted on a subcutaneous level (Fig.33.2).
End-stage renal insufciency (ESRD) in itself
behaves as a form of comorbidity in preexisting situations causing complications that lead to the formation of necrotic tissues, as well as exacer­bation in the appearance of cutaneous ulcerous lesions. Lastly, as a direct cause, it leads to com­plications that progress to ulcers.
© The Author(s) 2024 L. Téot et al. (eds.), Skin Necrosis, https://doi.org/10.1007/978-3-031-60954-1_33
225
226
nT
Table 33.1 KDOQI classication
E. Ricci
Stage GFR* Descriptio
1 90+ Normal kidney function but urine findings or structural
260-89 Mildly reduced kidney function, and other findings (as for
3A 3B
415-29 Severely reduced kidney functionPlanning for endstage renal failure. More
5 <15 or on
45-59 30-44
dialysis
abnormalities or genetic trait point to kidney disease
stage 1) point to kidney disease
Moderately reducedkidney function Observation, control of blood pressure
Very severe, or endstage kidney failure (sometimes call
established renal failure)
reatment stage
Observation, control of blood pressure.
More on management of Stages 1 and 2 CKD.
Observation, control of blood pressure and risk factors. More on management of
Stages 1 and 2 CKD.
and risk factors. More on management of
Stage 3 CKD.
on management of Stages 4 and 5 CKD.
Treatment choices. More o
management of Stages 4 and 5 CKD.
n
Fig. 33.1 Nephrogenic dermal brosis (NDF)

33.1 Comorbidity

ESRD in itself leads to a state of fragility in the patient, with reduction of the immune system defences and consequently a greater incidence of infective phenomena. The reduction in renal clearing leads to an accumulation of catabolites that in themselves have an inammatory action. A situation of increased phlogosis means healing times are lengthened, with a slowing down both of the retraction and the re-epithelialisation phe­nomena. Some examples are the following: the frequent association with diabetes leads to a prognostic deterioration with an increase in the number of amputations and the evolution in a necrotic direction of the diabetic foot [5, 6]. Patients who have been in dialysis for long peri-
Fig. 33.2 Subcutaneous calcication in NDF
ods present a high rate of arterial disease which, with the phenomena of vascular calcinosis, may lead to the development of cutaneous necrotic ulcers of an arterial type [7]. Al Ghazal [8] also suggests a correlation with the development of forms such as pyoderma gangrenosum. Yates [9] has noted an increase in infections from MRSA in patients who have ulcers with ESRD. The cutaneous blood ow is signicantly reduced in dialysis patients compared with healthy control group [10]. Tercercedor [11] suggests that the frequency of malignant skin tumours is increased in dialysis patients; he describes skin carcinoma­tous lesions in 2.4% of patients. In severe case, kidney transplantation can reverse the skin lesions and overcome the symptoms improving the quality of life [12, 13].
33 Renal Insuciency andNecrosis
227

33.2 Exacerbation

The forms in which we may dene ESRD as exacerbation are forms in which there is a net increase in the incidence of cutaneous ulcerous disease in the presence of the combination. These are not actual syndromes, because there is no direct cause-effect relationship, but the frequent association, besides complicating the situation, leads to a therapeutic approach that must be combined.
The antiphospholipid antibody form, of itself, besides the cutaneous damage involved, may lead to renal damage. There is therefore an effect on nega­tive synergic terms between the two forms [14], which on the one hand can lead to a worsening of the nephrological situation while on the other, in patients with ESRD and cutaneous damage, the form of hypercoagulability facilitates the develop­ment of ulcers [15] (Fig.33.3) (see Chap. 18).
Ulcers from anticoagulants, or cutaneous necrosis from anticoagulants, are particularly fre­quent in patients with renal insufciency. The increase in the coagulation time, combined with the reduced capacity for elimination of the medi­cine, facilitates the development of haematomas. The skin, modied in the presence of ESRD to become more rigid and fragile, tends to be dam­aged more easily in the case of even minor trau­mas. A haematoma, which itself tends to compress the skin, can easily lead to the onset of necrotic phenomena (see Chap. 13). The same
Fig. 33.3 Antiphospholipid antibody syndrome with ESRD V stage with skin ulcers
mechanism is involved in the use of heparin, especially in patients subjected to dialytic treatment.
Some vasculitic forms are characterised by contemporaneous damage at the level of the renal glomerular, such as in the antiphospholipid anti­body form, involving a synergic effect. The coag­ulative disorders, damage on a cutaneous level secondary to ESRD, lead to a vicious circle that moves beyond the simple situation of underlying comorbidity (see Chap. 20).

33.3 Direct Cause

Patients with systemic vasculitis may simultane­ously develop necrotising skin lesions and kidney injury in the form of acute glomerulonephritis [16]. A broad spectrum of autoimmune disorders may be responsible for the above manifestations, including systemic lupus erythematosus, anti­neutrophil cytoplasmic antibody (ANCA) vascu­litis, cryoglobulinaemia, cryobrinogenaemia, and polyarteritis nodosa.
The ulcerous form directly linked to ESRD is the so-called calciphylaxis or calcied uraemic arteritis (CUA). This is a rare ulcerous form often with an inauspicious prognosis, which begins with necrotic cutaneous ulcerations with unde­ned edges (Fig.33.4) and can spread extensively (see Chap. 14). Recognised risk factors for CUA include diabetes mellitus, poorly controlled sec­ondary hyperparathyroidism along with the use of calcium-based phosphorus binders, obesity, female gender, history of RRT, white ethnicity, low albumin level, and impairment of the vitamin K pathway because of warfarin use [17]. CUA leads to substantial morbidity, prolonged hospi­talisation, and mortality rates as high as 80%. The clinical presentation is frequently character­ised by the development of proximal (and often symmetrical) lesions on the buttocks, thighs, and abdomen with less common involvement of the acral regions. Nonhealing wounds provide an opportunity for infection with multiple microor­ganisms and sepsis.
In a patient with ESRD, it is necessary to carry out a differential diagnosis, especially for the